ArticleIn vivo (Athens, Greece)
Effect of Partial Splenic Embolization on Immune Environment and Hepatic Function in Cirrhosis Patients With Portal Hypertension.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Characteristics and Technical Outcomes of Microballoon Catheter-assisted Partial Splenic Embolization.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimIn hepatocellular carcinoma (HCC), portal hypertension (PHT) during the advanced stages of cirrhosis leads to splenomegaly. Additionally, the immune environment is an important factor in HCC treatment. Splenectomy and partial splenic embolization (PSE) are expected to improve this condition; however, data on the effects of PSE on immune function are limited. Therefore, we investigated the effects of PSE on the immune environment and hepatic function in patients with PHT-related cirrhosis. PATIENTS AND
methodsThe study included 117 of 238 patients who underwent PSE for PHT at our Department between 2011 and 2024 and were followed-up for more than 12 months, excluding those who underwent additional procedures concurrent with PSE. Changes in blood cell counts, hepatic function and immunological parameters including the neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio, were examined.
resultsThe mean splenic volume, mean splenic infarction volume, and splenic infarction rate were 396.64 ml, 222.8 ml, and 58.6%, respectively. The preoperative splenic volume was inversely correlated with platelet and lymphocyte counts. The platelet count increased from 7.3 to 10.4 at 1 year; the platelet-albumin-bilirubin score improved from -2.38 to -2.49 (
conclusionPSE not only improved platelet counts, but also increased lymphocyte counts and improved the NLR. PSE-induced improvements in the immune environment may be useful for introducing combination immunotherapy for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.